Myeloma Trial, Recruiting NCT03375619 Sponsor: Medical College of Wisconsin Condition: Myeloma
Back to Myeloma

Myeloma Trial, Recruiting

NCT03375619
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

"Who might be able to join this trial:

  • You must have already enrolled in a CAR-T cell therapy study at Froedtert Hospital & the Medical College of Wisconsin.

Who may not be able to join:

  • There are no rules that would stop someone from joining this trial, as long as they meet the requirement above.

Important: Always verify eligibility with the trial site directly before applying."

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Nirav Shah, Medical College of Wisconsin

Phone: 414-805-8900

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Medical College of Wisconsin
Registry
ClinicalTrials.gov
Start date
1 December 2017
Est. completion
1 January 2035

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change from baseline in the incidence of a new malignancy at 5 years.; Change from baseline in the incidence of a new malignancy at 10 years.; Change from baseline in the incidence of a new malignancy at 15 years.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov